平胃散加减方辅助治疗新型冠状病毒肺炎物质基础及作用机制的网络药理学探究  

Material basis and mechanism of Pingwei powder addition or subtraction as adjuvant treatment for corona virus disease 2019 by network pharmacology

作　　者：钱伟[1] 白桦[1] 孙雪松[1] 曹戬 胡元会[2] 郝志晔 QIAN Wei;BAI Hua;SUN Xue-song;CAO Jian;HU Yuan-hui;HAO Zhi-ye(Southern Branch of Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 102618;Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053)

机构地区：[1]中国中医科学院广安门医院(南区),北京102618 [2]中国中医科学院广安门医院,北京100053

出　　处：《中南药学》2020年第8期1311-1317,共7页Central South Pharmacy

基　　金：北京市科协金桥工程种子资金项目(No.ZZ19053);本部专家学术经验传承(No.Y2018SC-01)。

摘　　要：目的探讨平胃散加减方辅助治疗新型冠状病毒肺炎(COVID-19)的临床疗效、物质基础及可能的作用机制。方法将12例寒湿证候COVID-19患者分为西医治疗组(α-干扰素联合阿比多尔)和联合治疗组(加用平胃散加减方),比较治疗14 d前后中医症候变化,观察治愈出院、死亡出院人次及住院天数。通过网络药理学研究筛选平胃散加减方有效成分和作用靶标,并预测其辅助治疗COVID-19的作用机制。结果治疗14 d后联合治疗组较西医治疗组中医症候改善更显著(4.15±1.25 vs 1.80±0.75);12例患者均治愈出院,联合治疗组住院天数较西药治疗组更短[(23.29±1.98)d vs(16.60±1.36)d]。本研究共筛选得到平胃散加减方86个活性成分,与COVID-19重合靶标50个,预测出与疾病相关的作用通路多条,主要涉及生物膜质功能、细胞凋亡及基因复制/转录等方面。结论平胃散加减方联合西医药物治疗COVID-19可以显著改善中医证候,缩短住院天数,疗效理想。本研究预测得到平胃散加减方治疗COVID-19的主要活性成分均为黄酮类化合物;可能通过多靶点调控生物膜质功能、细胞凋亡及基因复制/转录等机制对COVID-19起到治疗作用。本研究补充了COVID-19寒湿症候方药的临床疗效与药理学研究,对进一步研究COVID-19诊疗方案具有一定意义。Objective To determine the clinical effect,material basis and mechanism of Pingwei powder addition or subtraction as an adjuvant treatment for corona virus disease 2019 (COVID-19).Methods Twelve patients with cold and wet syndrome of COVID-19 were divided into two groups.The western medicine treatment group was given α-interferon combined abidor.The combined treatment group was given α-interferon combined with abidor and Pingwei powder.The changes in traditional Chinese medicine (TCM) symptoms before and after a 14 day treatment were compared.The number of patients discharged,death and hospital stay were all observed.The active ingredients and targets of Pingwei powder were screened with network pharmacology,and the mechanism of action of its adjuvant therapy for COVID-19 was predicted.Results After the 14 day treatment,TCM syndrome scores in the combined treatment group improved more significantly than those in the western medicine group (4.15±1.25 vs 1.80±0.75).All the 12 patients were cured and discharged,and the length of stay in the combined treatment group was shorter than that in the western medicine treatment group[(23.29±1.98) d vs (16.60±1.36) d].In this study,86 active components of Pingwei powder were screened,and 50 targets overlapped with COVID-19.Several disease-related pathways were predicted,mainly involving biofilm function,cell apoptosis and gene replication/transcription and so on.Conclusion The Pingwei powder addition or subtraction with western medicine for COVID-19 can significantly improve the TCM syndrome and shorten the length of hospital stay.This study predicts the main active components of Pingwei powder for COVID-19 were flavonoids,whose mechanisms cover multi-target regulation of biofilm function,cell apoptosis and gene replication/transcription and so on.

关 键 词：网络药理学 平胃散加减方 新型冠状病毒肺炎 靶点 作用机制 

分 类 号：R96[医药卫生—药理学]